Concepts and challenges of biosimilars to mitigate the oncology drug expenses

Abstract

Biosimilars is way more likely to genuine generic drugs of the innovator. Time to time expiry of generic drugs helps manufacturer to think about biosimilars which has wide cost effectiveness as well as expanded patient accessibility to medicines especially for malignancy patients. This article gives a refreshed audit of the biosimilar pharmaceutical products affirmed for disease treatment in the US and EU through strict pre-clinical, clinical as well as pharmacovigilance touchstones. Diverse oncological biosimilar drugs that are right now being utilized like epoetins (alpha and zeta), filgrastim, as well as mAb (rituximab, trastuzumab and bevacizumab) are being exhibited in this article.